Hal Barron (Endpoints News)
March 11, 2021 06:58 AM ESTUpdated March 12, 01:29 PM
R&D
Coronavirus

Glax­o­SmithK­line, Vir gear up for EUA, cit­ing ear­ly PhI­II Covid-19 win with 'best-in-class' an­ti­body con­tender

Amber Tong

Glax­o­SmithK­line’s big bet on Vir Biotech­nol­o­gy and its an­ti­body tech­nol­o­gy has paid off.

The part­ners say they are now ready to ap­ply for an emer­gency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times